The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports


Karuna Shares Jump 375% Higher on Phase 2 Acute Psychosis Treatment Trial Data

  ()
Shares of Karuna Therapeutics, which completed an IPO in July 2019, soared more than 375% higher after the firm reported that its KarXT met primary endpoint in a phase 2 clinical trial of acute psychosis in patients with schizophrenia. read more >

Sales of Antibiotic Alternative for Livestock Feed Accelerate in Asia

  ()
With antibiotic resistance a major health issue, the search is on for effective alternatives to replace antibiotics in livestock feed to promote growth. read more >

Plus Therapeutics Shares Trade Higher on Q3 Earnings and Business Restructuring

  ()
Plus Therapeutics shares traded higher after the firm reported Q3/19 financial and business results. In the most recent quarter, the company completed the change of its name, relocated its headquarters to Austin, and raised $15 million for R&D and working capital. read more >

Exicure's Collaboration with Allergan on Treating Hair Loss Disorders Sends Shares Higher

  ()
Shares of Exicure Inc. opened 30% higher after the firm reported that it entered into a collaboration agreement with Allergan to discover and develop SNA-based treatments for hair loss disorders. The terms of the deal provide for a $25 million upfront payment to Exicure with the potential to grow to $750 million. read more >
News Update

Clinical Trial Results for Alcoholic Hepatitis Drug Delivered in Webcast

News Update
  ()
The online presentation coincides with The Liver Meeting 2019, at which data also are shared. read more >

FDA Approval of Peanut Allergy Treatment Expected Next Year

Research Report
  ()
The current status, catalysts and outlook for the immunotherapy are discussed in a ROTH Capital Partners report. read more >
News Update

Biopharma Presents Data on Alcoholic Hepatitis Therapeutic at Liver Meeting

News Update
  ()
The company intends to follow up in 2020 with a Phase 2b clinical trial. read more >

Seachange in Mexico on Cannabis Could Benefit This Small Cap

Contributed Opinion
  ()
Technical analyst Clive Maund highlights a small-cap that may be poised to benefit from the recent Mexican Supreme Court decision on cannabis. read more >

Iovance Biotherapeutics Shares Rise 12% on Updated Phase 2 Melanoma Study Results

  ()
Shares of Iovance Biotherapeutics traded 12% higher after the firm reported updated clinical data from its phase 2 lifileucel metastatic melanoma trial. read more >

Could There Finally Be an Effective Treatment for Alzheimer's Disease?

  ()
ProMIS' preclinical treatment could possibly outshine Biogen's candidate. read more >

Aquestive Therapeutics Shares Up on Pipeline Update and Raised Full-Year 2019 Guidance

  ()
Aquestive Therapeutics Inc. shares traded 20% higher after the firm reported Q3/19 earnings and raised its FY/19 guidance. The firm states it expects to complete its NDA for Libervant buccal film near the end of this month. read more >

RedHill Biopharma Shares Rise 10% After Receiving FDA Approval for H. Pylori Treatment Drug Talicia

  ()
Shares of RedHill Biopharma Ltd. traded higher after the firm announced that the FDA has approved its Talicia delayed-release capsules for the treatment of H. pylori infection in adults. The firm plans to commence distribution by its U.S. sales force in Q1/20. read more >

BeiGene Shares Up 35% on Amgen's $2.7 Billion Investment and China Partnership

  ()
Shares of BeiGene Ltd. traded 35% higher to a new a 52-week intraday high after announcing a commercialization agreement for of XGEVA (denosumab), KYPROLIS (carfilzomib), and BLINCYTO (blinatumomab) with Amgen Inc. in China. As part of the partnership, Amgen will invest $2.7 billion in BeiGene for 20.5% equity ownership. read more >

IVERIC bio Shares Double After Announcing Phase 2b AMD Topline Data

  ()
Shares of IVERIC bio traded 100% higher after reporting that it successfully met its primary endpoint in its Phase 2b age-related macular degeneration study for Zimura. read more >

Biotech's Topline Phase 3 HER2-Positive Breast Cancer Data 'Impresses'

Research Report
  ()
The results and commercial potential of the therapeutic are discussed in an H.C. Wainwright & Co. report. read more >
News Update

Biotech Develops Antibodies Targeting TDP-43 in Neurodegenerative Diseases

News Update
  ()
These therapeutic candidates add to those already in the firm's pipeline. read more >

Biogen Shares Rebound Strongly on Updated Phase 3 Alzheimer's Data and Q3 Earnings

  ()
Shares of Biogen Inc. soared after the firm announced plans to submit a Biologics License Application to the FDA in early 2020 for its Alzheimer's drug aducanumab based on new analysis of larger datasets from two phase 3 studies. The company also announced Q3/19 earnings. read more >

Clinical Trial Starts for Biopharma's Antifungal in Cryptococcal Meningitis

Research Report
  ()
The details of this study and a second one are outlined in a ROTH Capital Partners report. read more >

Dermira's Phase 2b Atopic Dermatitis Trial Results Send Shares 25% Higher

  ()
Dermira shares traded higher after the firm released positive data from its phase 2b study of lebrikizumab in patients with atopic dermatitis at the Las Vegas Fall Clinical Dermatology Conference. read more >

Protalix Shares Trade up 70% Upon Release of Phase 3 Fabry Disease Data

  ()
Shares of Protalix Biotherapeutics skyrocketed on much higher than average volume as the firm announced positive 12-month interim data from its BRIDGE Phase 3 open label switch-over study of pegunigalsidase alfa (PRX-102) for the treatment of Fabry disease. read more >

Achillion Pharma Shares Open 75% Higher After Alexion Buyout Offer

  ()
Shares of Achillion Pharmaceuticals traded much higher after the firm reported that it has agreed to be acquired by Alexion Pharmaceuticals for $930 million, or $6.30 per share in cash, along with the potential for an additional $2 per share if certain other specific clinical trial and regulatory milestones are met. read more >

Assembly Biosciences Stock Sizzles Following Phase 2a Announcement and Buy Rating from Mizuho

  ()
Good news is piling up for this healthcare stock engaged in the treatment of hepatitis B as it trades at 5X its average volume with a 30% stock price gain over previous close. read more >

Relmada Therapeutics Stock Soars on Phase 2 Depression Study Results

  ()
Shares of Relmada Therapeutics traded wildly after it announced Phase 2 results for its anti-depressant drug dextromethadone. The firm's shares have traded 100200% higher and the stock was halted several times trading due to extreme price volatility. read more >

Cerecor Shares Rise 13% on Sale of Pediatric Portfolio for $32 Million

  ()
Shares of Cerecor Inc. traded higher after reporting that it will sell its pediatric portfolio to Aytu BioScience for $32 million in a combination cash and stock deal. read more >

Technical Analyst Expects Health Technologies Firm to Break Higher

Contributed Opinion
  ()
Technical analyst Clive Maund outlines the reasons this stock might break higher. read more >
Showing Results: 1 to 25 of 118 Next

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts